Preclinical data continue to emerge supporting the optimal use of immune checkpoint inhibition with the primary tumor in place, due to higher mutation load, increased heterogeneity of mutations and greater potential for anti-tumor CD8 T cells expansion and cytokine release (10, 11). Here, CD8A is linked to neoplasm.